Patients with metastatic or locally advanced TNBC with PD-L1 expression on immune cells occupying ≥1% of tumor area have demonstrated survival benefit with combined therapy of Atezolizumab and Nab-Paclitaxel [46]. Here, CD274 is linked to neoplasm.